Metagenomi Therapeutics, Inc.: valuation

MGXNASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$0.69

November 13, 2026Market cap $26M

DCF calculator

What Ploutos Investor adds for Metagenomi Therapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 3 fiscal years, from 2023
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Valuation today

What the market pays for the company's earnings, cash flow, book value and revenue at $0.69 (November 13, 2026), beside the median of its past fiscal years.

EV / EBIT
–
EV / Revenue
–
Earnings yield
–
FCF yield
–
Market cap
$26M
enterprise value –

DCF calculator

What is Metagenomi Therapeutics worth on your own assumptions?

The DCF calculator opens with the company's figures already filled in from its filings. You set how fast its cash flow grows and the return you ask for, and see the value those assumptions give.

Free cash flow, 12 months
-$84M
Net cash
$102M
Shares
37.62M
FCF, 5-year average a year
–
Revenue, 5-year average a year
-25.0%
Price
$0.69
Value MGX

The full analysis

What do Metagenomi Therapeutics's filings show?

The multiples say what the market pays for Metagenomi Therapeutics. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about MGX's valuation

Didn't find what you were looking for?

Ask us
How do I work out what MGX is worth?

With the DCF calculator: it opens with Metagenomi Therapeutics's figures from its filings, you enter your assumptions for growth and the return you ask for, and see the value they give. The company pages give no price target of their own. A full analysis gives a fair-value range, which is an estimate, not a target.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. The estimated fair value, where shown, is our estimate, labelled as one: not a fact, not a score and not a recommendation to buy or sell.